Trachoma

Summary

Trachoma (MONDO:0001249) is a disease and 31 clinical trials. Top therapeutic interventions include azithromycin, albendazole, and fluorometholone. A subtype of chlamydia trachomatis infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 31

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	trachoma
Mondo ID	MONDO:0001249
MeSH	D014141
DOID	DOID:11265
ICD-10-CM	A71
ICD-11	372424530
SNOMED CT	2576002
UMLS	C0040592
MedGen	52801
Is cancer (heuristic)	no

Disease family

This is a subtype of chlamydia trachomatis infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › commensal bacterial infectious disease › chlamydia trachomatis infectious disease › trachoma

Related subtypes (3): inclusion conjunctivitis, lymphogranuloma venereum, pneumonia caused by chlamydia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 31.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	17
Not specified	8
PHASE3	3
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03335072	PHASE4	ACTIVE_NOT_RECRUITING	Kebele Elimination of Trachoma for Ocular Health
NCT00221364	PHASE4	COMPLETED	Trachoma Elimination Follow-up
NCT00286026	PHASE4	WITHDRAWN	Azithromycin in Control of Trachoma II
NCT00322972	PHASE4	COMPLETED	Trachoma Amelioration in Northern Amhara (TANA)
NCT00347607	PHASE4	COMPLETED	Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania
NCT00347763	PHASE4	COMPLETED	Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
NCT00348478	PHASE4	COMPLETED	Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger
NCT00522860	PHASE4	COMPLETED	A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery
NCT00618449	PHASE4	COMPLETED	Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
NCT00792922	PHASE4	COMPLETED	Partnership for Rapid Elimination of Trachoma
NCT01202331	PHASE4	COMPLETED	Tripartite International Research for the Elimination of Trachoma
NCT01903057	PHASE4	WITHDRAWN	Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
NCT03523156	PHASE4	WITHDRAWN	Trachoma Elimination Study by Focused Antibiotic (TESFA)
NCT03570814	PHASE4	COMPLETED	Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin
NCT04185402	PHASE4	COMPLETED	Azithromycin Reduction to Reach Elimination of Trachoma
NCT05634759	PHASE4	COMPLETED	Enhancing the A in SAFE for Trachoma
NCT06289647	PHASE4	WITHDRAWN	Azithromycin Reduction to Reach Elimination of Trachoma B
NCT00356720	PHASE3	COMPLETED	Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma
NCT02176057	PHASE2/PHASE3	WITHDRAWN	Nepal Elimination of Trachoma Study
NCT02754583	PHASE3	COMPLETED	Sanitation, Water, and Instruction in Face-washing for Trachoma I/II
NCT03676140	PHASE3	COMPLETED	Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
NCT03813069	PHASE2	COMPLETED	Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma
NCT03926728	PHASE1	COMPLETED	Safety and Immunogenicity of a Chlamydia Vaccine CTH522
NCT07322302	Not specified	RECRUITING	RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)
NCT00886015	Not specified	COMPLETED	Modified Instrumentation for Surgery to Correct Trichiasis
NCT01767506	Not specified	COMPLETED	A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
NCT01949454	Not specified	COMPLETED	Fluorometholone as Ancillary Therapy for TT Surgery
NCT02373657	Not specified	COMPLETED	Water Uptake for Health in Amhara Pilot
NCT02655432	Not specified	WITHDRAWN	Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population
NCT03997487	Not specified	TERMINATED	Smartphone App for Taking Images of Conjunctivae
NCT04002726	Not specified	TERMINATED	App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AZITHROMYCIN	4	7
ALBENDAZOLE	4	1
FLUOROMETHOLONE	4	1
IVERMECTIN	4	1
TETRACYCLINE	4	1
WATER	4	1
CHEMBL4299381	0	11
CHEMBL263291	0	1
CHEMBL4082099	0	1
CHEMBL4788951	0	1
CHEMBL1716015	0	1